All In Biotech

Drug Trial Radar · NCT06185764

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

A Phase 1/2, Randomized, Double-blind, Placebo-controlled Single- and Multiple-dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type 1

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

47

Actual

Start

Feb 20, 2024

Primary completion

Feb 2, 2027

Study completion Feb 2, 2027

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Dec 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.

Conditions

  • Myotonic Dystrophy Type 1 (DM1)

Interventions

  • VX-670Drug

    Solution for intravenous administration.

  • PlaceboDrug

    Solution for intravenous administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)Time frame: Part A: From Baseline up to Day 42; Part B: From Baseline and up to Day 168

Locations

26 sites in 10 countries. Site status is shown where the registry gives one.

  • Stanford Neuromuscular Research

    San Carlos, California

  • University of Florida Clinical Research Center

    Gainesville, Florida

  • University of Kansas Medical Center

    Fairway, Kansas

  • Boston Children's Hospital

    Boston, Massachusetts

  • Washington University School of Medicine / St. Louis Children's Hospital

    St Louis, Missouri

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Virginia Commonwealth University (Sanger Hall)

    Richmond, Virginia

  • Wesley Research Institute

    Auchenflower, Australia

  • Neuroscience Clinical Trials Unit, Alfred Brain

    Melbourne, Australia

  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

    Leuven, Belgium

  • Hopital de Chicoutimi

    Chicoutimi, Canada

  • Altasciences Montreal

    Montreal, Canada

  • McGIll University

    Montreal, Canada

  • University of Ottawa

    Ottawa, Canada

  • CHU Research Centre of Quebec

    Québec, Canada

  • Neuromuscular Reference Center Institute of Myology

    Paris, France

  • Ludwig Maximilians Universitaet Muenchen

    München, Germany

  • Centro Clinico NeMO

    Milan, Italy

  • Maastricht University Medical Center

    Maastricht, Netherlands

  • Hospital Universitario y Politécnico La Fe

    Valencia, Spain

  • Clinical Research Facility, Queen Elizabeth University Hospital

    Glasgow, United Kingdom

  • Leonard Wolfson Experimental Neurology Centre CRF

    London, United Kingdom

  • St. George's University Hospital

    London, United Kingdom

  • Salford Royal Hospital

    Salford, United Kingdom

  • Royal Hallamshire Hospital

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.